



Tokai Pharmaceuticals, Inc.  
255 State Street, 6<sup>th</sup> Floor  
Boston, MA 02109

March 3, 2017

U.S. Securities and Exchange Commission  
100 F Street, N.E.  
Washington, D.C. 20549

Re: Notice of disclosure filed in Exchange Act Annual Report under Section 219 of the Iran Threat Reduction and Syria Human Rights Act of 2012 and Section 13(r) of the Exchange Act

To Whom it May Concern:

Pursuant to Section 219 of the Iran Threat Reduction and Syria Human Rights Act of 2012 and Section 13(r) of the Securities Exchange Act of 1934, as amended, notice is hereby provided that Tokai Pharmaceuticals, Inc. has made disclosure pursuant to those provisions in its Annual Report on Form 10-K for the fiscal year ended December 31, 2016, which was filed with the Securities and Exchange Commission on March 3, 2017.

Respectfully submitted,

TOKAI PHARMACEUTICALS, INC.

By: /s/ Jodie P. Morrison

Name: Jodie P. Morrison

Title: President and Chief Executive Officer